President Donald Trump and the Food and Drug Administration (FDA) announce the emergency use authorization of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by the FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances. The FDA said more than 70,000 patients have been treated with convalescent plasma, but they have not yet obtained enough randomized clinical trial data on convalescent plasma for COVID-19. Some of those trials are underway.
President Donald Trump and Food and Drug Administration announce the emergency use authorisation issue of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances.
President Donald Trump and Food and Drug Administration announce the emergency use authorization issue of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances.
President Donald Trump and theFood and Drug Administration announce the emergency use authorization of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances.TheFDAsaidmorethan70,000patientshavebeentreatedwithconvalescentplasma,buttheyhavenotyetobtainedenoughrandomizedclinicaltrialdataonconvalescentplasmaforCovid-19.Someofthosetrialsareunderway.
President Donald Trump and the Food and Drug Administration (FDA)announce the emergency use authorization of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by theFDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances. The FDA said more than 70,000 patients have been treated with convalescent plasma, but they have not yet obtained enough randomized clinical trial data on convalescent plasma for COVID-19. Some of those trials are underway.